1. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
- Author
-
Muchtar, Eli, Gatt, Moshe E., Rouvio, Ory, Ganzel, Chezi, Chubar, Evgeni, Suriu, Celia, Tadmor, Tamar, Shevetz, Olga, Lavi, Noa, Shochat, Tzippy, Cohen, Yael C., Avivi, Irit, Raanani, Pia, and Magen, Hila
- Subjects
- *
MULTIPLE myeloma treatment , *PROTEASOME inhibitors , *SALVAGE therapy , *CANCER relapse , *BORTEZOMIB , *DRUG resistance in cancer cells , *DRUG efficacy , *THERAPEUTICS , *CANCER treatment - Abstract
Carfilzomib has been established in previous years as a treatment for patients with relapsed and/or refractory multiple myeloma (RR-MM). A retrospective multicentre study to evaluate the clinical use of carfilzomib for RR-MM outside of a clinical trial setting was conducted by our group. One hundred and thirty-five patients were included. All patients had been previously exposed to bortezomib and 93% had also been treated with lenalidomide. The vast majority of patients received carfilzomib as part of a two- or three-drug combination. The overall response rate was 47·2%. Multivariate analysis revealed bortezomib resistance, lenalidomide resistance and albumin <35 g/l to negatively impact the likelihood of achieving response. The median duration of response was 8·4 months, and was significantly higher in patients receiving three-drug combination and patients presenting without extramedullary disease. The median progression-free survival and overall survival for the entire cohort was 4·9 months (95% confidence interval [CI] 3·8-6·4) and 12·2 months (95% CI 9-not reached), respectively. Toxicity was manageable, although treatment-related death was seen in 5% of patients. In the setting of progressive multiple myeloma, carfilzomib in a combination regimens yields effective results with a manageable toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF